Saturday 2 December 2017 photo 7/45
|
Aim high trial pdf suite: >> http://wme.cloudz.pw/download?file=aim+high+trial+pdf+suite << (Download)
Aim high trial pdf suite: >> http://wme.cloudz.pw/read?file=aim+high+trial+pdf+suite << (Read Online)
doi 10.1056 nejmoa1300955
accord lipid trial
effects of extended-release niacin with laropiprant in high-risk patients
hps 2 thrive protocol
nejm niacin study
niacin clinical trials
va hit trial
hps2-thrive trial
TO THE EDITOR: The results of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial were published in the Journal in 2011. This study showed no incremental clinical benefit from the addition of high-dose extended-release niacin
17 Jul 2014 To the Editor: The results of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial were published in the Journal in 2011.1 This study showed no incremental clinical benefit from the addition of high-dose
29 Mar 2016 Funding: The Atherothrombosis Intervention in Metabolic syndrome with low high-density lipoprotein/high triglycerides: Impact on Global Health (AIM-HIGH) study was supported by the National Heart, Lung, and Blood Institute ( U01 HL081616 and U01 HL081649 ) and by an unrestricted grant from AbbVie,
15 Nov 2011 (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.) Full Text of Discussion Read the Full Article. Curve for the Primary End Point. Table 1 Baseline Demographic and Clinical Characteristics of the Study Patients.
2 Feb 2011 The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic
15 Nov 2011 2601 Fourth Ave., Suite 200, Seattle, WA. 98121, or at ruthm@axioresearch.com. * Additional investigators in the Athero- thrombosis Intervention in Metabolic. Syndrome with Low HDL/High Triglyc- erides: Impact on Global Health Out- comes (AIM-HIGH) trial are listed in the Supplementary Appendix
15 Dec 2011 AIM-HIGH was designed to determine whether raising HDL with niacin, while (optimally) lowering LDL with statin therapy, would. vCV events in those with . Lipid Landmark Trials: www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-lipid%20agents-major%20trials.pdf. References: 1.
15 Nov 2011 November 15, 2011 (Orlando, Florida) — The AIM-HIGH trial and the future of niacin remained the focus of hot debate following presentation of the full results here at the American Heart Association (AHA) 2011 Scientific Sessions, with the scheduled discussant blasting the study as being far too short and
7 Nov 2017 List of Abbreviations. 4. 1.0 Executive Summary. 5. 2.0 Background and Rationale. 10. 3.0 Study Objectives. 15. 4.0 Study Design. 16. 4.1 General Review. 16. 4.2 Study Committees. 17. 4.3 Randomization and Duration of Study Participation. 18. 4.4 Selection of Patients. 18. 4.5 Treatment Protocol. 23.
In this randomized controlled trial involving 674 patients, the effect of interferon alfa-2a (3 megaunits three times per week for 2 years or until recurrence) on overall survival (OS) and recurrence-free survival (RFS) was compared with that of no further treatment in radically resected stage IIB and stage III cutaneous malignant
Annons